Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC) - Episode 10

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

, , ,

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
    EP. 2: Available Staging Systems for Cutaneous Squamous Cell Carcinoma
    EP. 3: Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
    EP. 4: Defining Resectability in CSCC
    EP. 5: Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
    EP. 6: Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
    EP. 7: Evolving Treatment Paradigm of Resectable CSCC
    EP. 8: Clinical Experience With Neoadjuvant IO Therapy in Melanoma
    EP. 9: Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
    Now Viewing
    EP. 10: Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
    EP. 11: CSCC: Translating Cemiplimab Data Into Practice
    EP. 12: Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
    EP. 13: Best Practices in Multidisciplinary Care for CSCC
    EP. 14: CSCC: Escalating Therapy for High-risk Patients
    EP. 15: Practical Advice on the Evolving Management of CSCC
    x